Teva launches new dosage option for hypertension therapy

Teva has announced the launch of a new dosage option for nebivolol, its approved generic therapy for essential hypertension.

The addition of nebivolol 2.5mg tablets represents a market first, as there is no brand equivalent to this strength of the drug. Original supplier Menarini Farmaceutica Internazionale manufactures the branded version, Nebilet, in the 5mg strength only.

Since Teva also supplied a 5mg version of the drug, it will help to cement the company's position as one of the UK's top ten pharmaceutical manufacturers.

Paul Burden, interim commercial director at Teva, said: "We are delighted to be able to add this strength of nebivolol to our range and to demonstrate our ongoing commitment to pharmacy."

Last October, the firm was named the UK's generics manufacturer of the year for an unprecedented 11th consecutive year at the annual Pharmacy Business Awards. It won the accolade following a vote by pharmacists across the country conducted by Pharmacy Business magazine.